FDA Greenlights Phase 3 Trial of Denifanstat for Moderate to Severe Acne
SGMT has more than doubled off its 52-week low of $4.5.
Summary
The FDA cleared Sagimet's IND for denifanstat in moderate to severe acne, allowing the Phase 3 trial to proceed—a key step in the company's pivot to dermatology.
Key Events · Product Development and Regulatory · SGMT
-
FDA Clears Phase 3 Acne Trial
The FDA issued a 'Study May Proceed' letter for denifanstat in moderate to severe acne, clearing the IND application.
-
Strategic Pivot to Dermatology
This milestone advances Sagimet's pivot toward acne, with a U.S. Phase 3 trial planned for H2 2026.
-
Cash Runway Supports Development
As of Q2 2026, the company reported $257.6 million in cash, sufficient to fund the Phase 3 program.
-
Next Milestone: Trial Initiation
Phase 3 trial initiation is expected in H2 2026, with data readout likely in 2027-2028.
Analysis · SGMT · Life Sciences
A major regulatory milestone has been reached: Sagimet Biosciences received FDA clearance to begin a Phase 3 clinical trial of denifanstat for moderate to severe acne. This de-risks the acne program and validates the company's strategic pivot toward dermatology. The trial is expected to start in H2 2026, and positive results could open a large commercial market. With $257.6 million in cash, the company has runway through the trial.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGMT was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $574.5M. The 52-week trading range was $4.50 to $10.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.